with LIN and after at least 3 days of combined therapy were analysed by liquid chromatography (HPLC). Oral VCZ clearance (CL/F in L/h) was estimated before (CL/Fb) and during treatment with LIN (CL/Fd LIN). It was assumed as VCZ therapeutic range 1.5–4.5 mcg/mL in Candida spp. infections and 2–4.5 mcg/mL in Aspergillus spp. Demographic variables (age, sex), treatment (dosing schedule, date and time of each administration), clinical (diagnosis, microbiological information, etc.) and kinetics (date and time of each sample extraction) were collected.

**Results** Five patients were analysed with a median age of 67 years (range: 57–73), all of them males. Mean daily dose ±SD administered were 454.5±157.2 mg (VCZ) and 1,200 mg (LIN). Serum baseline concentration of VCZ before LIN was 2.7±0.8 mcg/mL. CL/Fb and CL/Fd of VCZ were, respectively, 6.3±1.7 L/h and 22.09±11.74 L/h, which represents a large increase of 250%. VCZ and LIN interaction generated infra-therapeutic VCZ concentrations in 80% of patients (n=4). Three patients had to change anti-infective treatment and two patients required increased VCZ dose up to 75% to reach at least the lower limit of the therapeutic range.

**Conclusion** Adding LIN to VCZ treatment increases VCZ clearance between 250%–700% and serum antifungal concentrations decrease clinically. This translates into a loss of effectiveness in antifungal treatment in 80% of cases. Therefore, the use of this combination is contraindicated and if clinically necessary, new antifungal treatment is recommended to ensure the effectiveness of antifungal treatment.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**


No conflict of interest.

---

**4CPS-059 EFFECTIVENESS OF MEROPENEM TREATMENT IN CRITICAL PATIENTS: PHARMACOKINETIC STUDY**

Al Idoate*, A Aldaz. Clínica Universitaria de Navarra, Pharmacy, Pamplona, Spain

10.1136/ejhpharm-2019-eahpconf.208

**Background** Pharmacokinetic/pharmacodynamic efficacy index (PK/PD) for carbapenems, in critical patients, is the maintenance of a free concentration drug, 4–5 times above the minimum inhibitory concentration (MIC) in the isolated germ during 100% of the dosage range. Ensuring this goal is important and requires the use of pharmacokinetic monitoring (TDM).

**Purpose** Analyse the efficacy of pharmacokinetic optimised meropenem’s regimen based on PK/PD criteria and compare it with empirical carbapenem’s regimen adjusted by renal function in patients admitted to the intensive care unit.

**Material and methods** Naturalistic retrospective, observational cohort study, carried out in critically ill patients treated with meropenem from May 2011 to December 2017. Patients were divided into two cohorts: cohort A if they had pharmacokinetic intervention or cohort B if not. In pharmacokinetic analysis two serum samples per patient were extracted (peak and elimination point) to quantify total and free concentration of meropenem. Individual pharmacokinetic parameters were estimated by the Sawchuk–Zaske method to find out what percentage of time, free concentration exceeded four times MIC of isolated germ and dosage regimen was adjusted when necessary. When CMI was not available, the epidemiological limit of EUCAST(ECOFF)2 mcg/mL was used.

**Clinical and bacteriological responses were the main goals. Data was analysed using STATA12.0. Propensity score (PS) of each patient was calculated and patients in cohort A were compared and paired one by one with those of cohort B with similar PS.**

**Results** One-hundred and fifty-six patients were included, 78 in each cohort after matching by PS. Main antimicrobial treatments were targeted (71.8% in cohort A and 73% in cohort B). Median duration of meropenem was 11 days (range: 2–31 days). In cohort A, dose adjustment was performed in 65% (n=51) of patients and in up to 88% (n=45) of them it was recommended to reduce dose or extend dosage range. Cohort A was associated with clinical improvement (OR: 1.624, 95% CI: 0.82 to 3.23, p=0.167), bacteriological (OR: 0.636, 95% CI: 0.27 to 1.48, p=0.292), fever resolution (OR: 2.415; 95% CI: 1.04 to 5.61, p=0.040), decreased inflammatory parameters (statistically significant PCR (p=0.0065) and procalcitonin (p=0.0099), lower hospital mortality (OR: 1.184; 95% CI: 0.52–2.68, p=0.685) and early mortality during first 14 days after hospital discharge (OR: 0.7055, 95% CI: 0.1184 to 4.76, p=0.761), against cohort B.

**Conclusion** Meropenem daily dose was decreased in 56% of critical patients monitored. TDM is important in fighting against antimicrobial resistance, it is a guarantee of safety and it allows a reduction in healthcare cost.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

https://www.ijaonline.com/article/S0924–8579(16)30268–0/fulltext

No conflict of interest.

---

**4CPS-060 PREVALENCE OF VANCOMYCIN-RELATED NEUTROPAENIA, THROMBOCYTOPAENIA AND ACUTE KIDNEY INJURY**

J Landa Alberdi*, L Lombara Saez, I Aldalur Uranga, A Zurutuza Lopez, D Garcia Echeverria, T Gonzalez Fernandez, MJ Gayan Lera, P Pascual Gonzalez, MP Bachiller Cacho, MP Carmona Oyaga. Hospital Universitario Donostia, Pharmacy Department, Donostia, Spain

10.1136/ejhpharm-2019-eahpconf.209

**Background** Vancomycin is a glucosamine antibiotic widely used to treat Gram positive related infections. It is well known for its nefrotoxic and ototoxic profile, but neutropaenia and thrombocytopaenia are not so well described.

**Purpose** The aim of this study was to describe the prevalence of some relevant vancomycin-related adverse events (AE): neutropaenia, thrombocytopaenia and acute kidney injury (AKI).

**Material and methods** This retrospective observational study was conducted in all patients admitted to Donostia University Hospital that received vancomycin during 2016 and 2017 and were monitored by the pharmacy department (PD).

**Exclusion criteria:** patients with neutropaenia, thrombocytopaenia or AKI prior to vancomycin therapy.

**Collected data:** diagnosis, absolute neutrophil count (ANC), absolute platelet count (APT) and creatinine clearance (CrCl), calculated with Cockcroft–Gault formula prior and during vancomycin therapy. Neutropaenia was defined as ANC<1000 cel/microL, thrombocytopaenia as APT <100.000 cel/microL and AKI as CrCl <60 ml/min or decrease in CrCl of 25%.